(phenylacetyl)cyanamide | 52770-96-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (phenylacetyl)cyanamide
• 英文别名: N-cyano-2-phenylacetamide
• CAS: 52770-96-4
• 化学式: C₉H₈N₂O
• 分子量: 160.175
• InChiKey: YFHYOTWTHOYZAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  52.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (phenylacetyl)cyanamide 在 吡啶 、 盐酸羟胺 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 N,N'-羰基二咪唑 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Synthesis and multiparametric evaluation of thiadiazoles and oxadiazoles as diacylglycerol acyltransferase type 1 inhibitors

  摘要：

  Chemical modulation of a formerly disclosed DGAT-1 inhibitor resulted in the identification of a compound with a suitable profile for preclinical development. Optimisation of solubility is discussed and a PK/PD study is presented. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.11.046
• 作为产物：
  描述：

  苯乙酰氯 、 氰胺 在 potassium hydride 作用下， 以 四氢呋喃 为溶剂， 以89.5%的产率得到(phenylacetyl)cyanamide
  参考文献：
  名称：

  Belletire, J. L., Synthetic Communications, 1988, vol. 18, # 16-17, p. 2063 - 2072

  摘要：

  DOI：

文献信息

• Acyl, N-protected .alpha.-aminoacyl, and peptidyl derivatives as prodrug forms of the alcohol deterrent agent cyanamide
  作者：Chul Hoon Kwon、Herbert T. Nagasawa、Eugene G. DeMaster、Frances N. Shirota

  DOI：10.1021/jm00160a021

  日期：1986.10

  were synthesized specifically as prodrugs, including benzoylcyanamide (2), pivaloylcyanamide (3), and 1-adamantoylcyanamide (4), as well as long- and medium-chain fatty acyl derivatives such as palmitoyl- (6), stearoyl- (7), and n-butyrylcyanamide (5). N-Protected alpha-aminoacyl and peptidyl derivatives of cyanamide were also synthesized, and these include N-carbobenzoxyglycyl- (10), hippuryl- (13)

  氰胺（H2NC与N相同）是一种有效的醛脱氢酶（AlDH）抑制剂，在治疗上用作一种醇类威慑剂，已知会以乙酰氰胺的形式快速代谢并排泄到尿液中（1）。根据我们的观察结果，即1在体内被脱乙酰基化为氰胺，尽管非常轻微，从而作为后者的前药形式的前体，专门合成了几种氰胺的酰基衍生物作为前药，包括苯甲酰基氰酰胺（2），新戊酰氰胺（ 3），1-金刚烷基氨酰胺（4），以及长链和中链脂肪酰基衍生物，例如棕榈酰-（6），硬脂酰基-（7）和正丁酰氰胺（5）。还合成了N-保护的氰酰胺的α-氨基酰基和肽基衍生物，包括N-碳苯甲氧基甘氨酰-（10），马尿酰基-（13），N-苯甲酰基-L-亮氨酸-（14），N-碳苯甲氧基氧基-L-亮氨酰-（18），N-碳苯甲氧基-L-焦谷氨酰-（22），L-焦谷氨酰基-L-亮氨酰-（19）和L-焦谷氨酰基-L-苯丙氨酰氰胺（20）。腹膜内给药后3小时，所有这些氰胺前药在大鼠体内均显着提高了
• [EN] DERIVATIVES OF OXADIAZOLE AND PYRIDAZINE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS<br/>[FR] DÉRIVÉS D'OXADIAZOLE ET DE PYRIDAZINE, LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPIE
  申请人：SANOFI SA

  公开号：WO2012011081A1

  公开（公告）日：2012-01-26

  The invention relates to compounds of formula (I): in which: n is equal to 0 or 1; D represents an oxygen atom or a bond; W represents a nitrogen atom or a -CH- group; X1 represents a nitrogen atom or a -CH=CH- group; X2 represents an oxygen atom or a nitrogen atom; X3 represents an oxygen atom or a nitrogen atom; one of X1, X2, X3 being other than a nitrogen atom, X2 and X3 not being an oxygen atom at the same time; R1, R2 are absent or represent, (i) independently of one another, a hydrogen atom or a (C1 -C4)alkyl group, (ii) R1 and R2 may form, with the carbon atom to which they are attached, a -(C3-C10)cycloalkyl- group; Y represents a -(C3-C10)cycloalkyl-, aryl or aryloxy group, said groups being optionally substituted with one or more substituents chosen from a halogen atom or a (C1 -C6)alkoxy group; Z1 is absent or represents an -NH- function; Z2 and Z3 are as defined in the description. The invention also relates to a process for preparing compounds of formula (I), compositions containing them and their application in therapeutics.

  本发明涉及公式（I）的化合物：其中：n等于0或1；D代表氧原子或键；W代表氮原子或-CH-基团；X1代表氮原子或-CH=CH-基团；X2代表氧原子或氮原子；X3代表氧原子或氮原子；其中X1、X2、X3中的一个不是氮原子，X2和X3不同时是氧原子；R1、R2不存在或代表（i）彼此独立的氢原子或（C1-C4）烷基；（ii）R1和R2可能与它们附着的碳原子形成-(C3-C10)环烷基-基团；Y代表-（C3-C10）环烷基、芳基或芳氧基团，所述基团可选地用一个或多个卤原子或（C1-C6）烷氧基取代；Z1不存在或代表-NH-功能；Z2和Z3如本说明书所定义。本发明还涉及制备公式（I）化合物的方法，包含它们的组合物以及在治疗学中的应用。
• DERIVATIVES OF OXADIAZOLE AND PYRIDAZINE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS
  申请人：Sanofi

  公开号：US20130137691A1

  公开（公告）日：2013-05-30

  The invention relates to compounds of formula (I): in which: n is equal to 0 or 1; D represents an oxygen atom or a bond; W represents a nitrogen atom or a —CH— group; X1 represents a nitrogen atom or a —CH═CH— group; X2 represents an oxygen atom or a nitrogen atom; X3 represents an oxygen atom or a nitrogen atom; one of X1, X2, X3 being other than a nitrogen atom, X2 and X3 not being an oxygen atom at the same time; R1, R2 are absent or represent, (i) independently of one another, a hydrogen atom or a (C1-C4)alkyl group, (ii) R1 and R2 may form, with the carbon atom to which they are attached, a —(C3-C10)cycloalkyl- group; Y represents a —(C3-C10)cycloalkyl-, aryl or aryloxy group, said groups being optionally substituted with one or more substituents chosen from a halogen atom or a (C1-C6)alkoxy group; Z1 is absent or represents an —NH— function; Z2 and Z3 are as defined in the description. The invention also relates to a process for preparing compounds of formula (I), compositions containing them and their application in therapeutics.

  本发明涉及公式（I）的化合物： 其中： n等于0或1； D代表氧原子或键； W代表氮原子或—CH—基团； X1代表氮原子或—CH═CH—基团； X2代表氧原子或氮原子； X3代表氧原子或氮原子； X1、X2、X3中的一个不是氮原子，X2和X3同时不是氧原子； R1，R2不存在或代表（i）彼此独立的氢原子或（C1-C4）烷基，（ii）R1和R2可以与它们附着的碳原子形成—（C3-C10）环烷基-基团； Y代表—（C3-C10）环烷基-、芳基或芳氧基团，这些基团可以选择性地被一个或多个卤素原子或（C1-C6）烷氧基置换； Z1不存在或代表—NH—功能； Z2和Z3如本说明中所定义。 本发明还涉及制备公式（I）的化合物的方法、含有它们的组合物以及它们在治疗学中的应用。
• Pharmaceutically active compounds and methods of use
  申请人：Durant J. Graham

  公开号：US20060270741A1

  公开（公告）日：2006-11-30

  The present invention relates to pharmaceutically acceptable compounds, including acylguanidine compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are particularly useful for the treatment or prophylaxis of neurological injury and neurodegenerative disorders.

  本发明涉及药学上可接受的化合物，包括酰基胍化合物，以及利用或包含一种或多种这样的化合物的治疗方法和制药组合物。本发明的化合物特别适用于治疗或预防神经损伤和神经退行性疾病。
• Cyanamides useful as reversible inhibitors of cysteine proteases
  申请人：Gilmore Thomas A.

  公开号：US06878706B1

  公开（公告）日：2005-04-12

  Compounds according to the following formula (I): wherein the variables Q and R 1 to R 6 are as described herein, which reversibly inhibit the cysteine proteases, such as cathepsins K, S, F, L and B; pharmaceutical compositions containing such compounds, and method of treating diseases and pathological conditions exacerbated by these cysteine proteases such as, but not limited to rheumatoid arthritis, multiple sclerosis and other autoimmune diseases, osteoporosis, asthma, Alzheimer's disease, atherosclerosis and endometriosis.

  根据以下公式（I）制备的化合物：其中变量Q和R1至R6如本文所述，可逆抑制半胱氨酸蛋白酶，如K、S、F、L和B型半胱氨酸蛋白酶；包含此类化合物的药物组合物，以及治疗由这些半胱氨酸蛋白酶恶化的疾病和病理状况的方法，例如但不限于风湿性关节炎、多发性硬化症和其他自身免疫性疾病、骨质疏松症、哮喘、阿尔茨海默病、动脉硬化和子宫内膜异位症。